Navigation Links
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of major depressive disorder.

EMSAM previously was marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers. Manufactured by Mylan subsidiary Mylan Technologies Inc. (MTI), EMSAM is a registered trademark of Somerset Pharmaceuticals Inc. In July 2008, Mylan acquired Watson Pharmaceutical Inc.'s 50 percent interest in Somerset, making the proprietary research and development company a wholly-owned subsidiary of Mylan.

Dey President Carolyn Myers, Ph.D., said, "I am very pleased that we have the opportunity to bring the marketing and distribution of EMSAM back into the Mylan family of companies. EMSAM was developed by Somerset in collaboration with Mylan and is manufactured by MTI. Now, we can market and distribute this important product through our specialty division, Dey, and the entire supply and distribution process will benefit from additional efficiencies and cost synergies going forward."

Dey, a Mylan company, is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies. For more information on Dey or its products, please visit www.dey.com.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
4. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
7. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
8. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
9. Dental Implant Market Insights Webinar
10. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... PA (PRWEB) , ... August 16, 2017 , ... While ... they are much more closely connected than one might think. A Mesh Is ... will open at the University City Science Center’s Esther Klein Gallery (EKG) on August ...
(Date:8/15/2017)... -- After spending the past two years building a state-of-the-art technology ... now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies ... data collection vis a vis their members, under their own brand. ... this offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a leader in sealed ... stay tightly sealed and perform efficiently for years. The downlights are ideal for ... aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and ...
(Date:8/14/2017)... ... August 14, 2017 , ... ... device-to-computer interconnect using USB or PCI Express, announced the release of SYZYGY™, a ... intended to satisfy the need for a compact, low cost, low pin-count, high-performance ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):